Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Cardiovascular disease (CVD) has emerged as a leading cause of morbidity and mortality in
HIVinfected individuals. The precise mechanisms underlying this increased cardiovascular risk
remain to be elucidated. Platelet hyperreactivity and increased platelet-monocyte aggregation
(PMA) are found in HIVinfectedpatients and may contribute to the excess cardiovascular risk
as platelets play a key role in the onset and progression of atherosclerosis and in acute
cardiovascular events. In addition, HIV-infected individuals frequently suffer from
persistent immune activation and inflammation. In a crosssectional study the investigators
recently showed that individuals using a regimen containing the integrase inhibitor
raltegravir have reduced platelet hyperreactivity and PMA compared to other antiretroviral
regimens. Other recent studies showed that raltegravir is associated with decreased immune
activation. Due to the inherent limitations of cross sectional studies, the investigators aim
to expand our findings in an intervention study. The investigators will conduct a randomized
control trial where the investigators switch patients to a integrase containing treatment
regimen to assay possible changes in platelet function and persistent immune activation.
Knowledge gathered in the proposed study can help understand and prevent cardiovascular
disease in patients treated for a HIV infection by reducing platelet hyperreactivity and
persistent immune activation.